MARKET

VCYT

VCYT

Veracyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.17
-8.21
-14.56%
After Hours: 48.17 0 0.00% 19:53 04/16 EDT
OPEN
56.01
PREV CLOSE
56.38
HIGH
56.20
LOW
46.18
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
86.03
52 WEEK LOW
21.19
MARKET CAP
3.23B
P/E (TTM)
-72.0461
1D
5D
1M
3M
1Y
5Y
Friday's ETF Movers: ICLN, XBI
Apr 16, 2021 (MarketNewsVideo.com via COMTEX) -- In trading on Friday, the iShares Global Clean Energy ETF is outperforming other ETFs, up about 3% on the...
MarketNewsVideo.com · 1d ago
Friday Sector Laggards: Biotechnology, Drugs
MarketNewsVideo.com · 1d ago
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 1d ago
8-K: VERACYTE, INC.
(EDGAR Online via COMTEX) -- FALSE000138410100013841012020-05-052020-05-0500013841012020-04-132020-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
BRIEF-Veracyte Says Keith Kennedy, CFO & COO, To Retire, Effective May 15
reuters.com · 2d ago
Veracyte CFO retires, expects Q1 prelim revenue growth of 17%
Veracyte (VCYT) announced that Keith Kennedy, CFO & COO, will retire from the company, effective May 15.Until the company searches a new CFO, Jane Alley, VP and corporate controller, will become
Seekingalpha · 2d ago
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May...
BusinessWire - BZX · 2d ago
Jaguar Health Upsizes At-the-Market Financing Program With Ladenburg Thalmann by $15.3 Million
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCYT. Analyze the recent business situations of Veracyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCYT stock price target is 84.83 with a high estimate of 95.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 323
Institutional Holdings: 72.10M
% Owned: 107.61%
Shares Outstanding: 67.00M
TypeInstitutionsShares
Increased
70
5.43M
New
56
1.11M
Decreased
72
4.19M
Sold Out
23
982.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Chief Executive Officer/Director
Bonnie Anderson
Chief Financial Officer/Chief Operating Officer
Keith Kennedy
Executive Vice President/General Counsel/Secretary
James Erlinger
Chief Accounting Officer/Vice President/Controller
Beverly Alley
Chief Scientific Officer
Giulia Kennedy
Independent Director
Fred Cohen
General Manager
Morten Frost
General Manager
John Hanna
Lead Director/Independent Director
John Bishop
Director
Muna Bhanji
Director
Jens Holstein
Independent Director
Frederick Cohen
Independent Director
Karin Eastham
Independent Director
Robert Epstein
Independent Director
Kevin Gordon
Independent Director
Evan Jones
No Data
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.